Founders Capital Management (Texas)’s Aratana Therapeutics, Inc. PETX Stock Holding History

Founders Capital Management (Texas)’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,000	Closed	-$5K	–	336
2019 Q2	$5K	Hold	1,000	–	–	﹤0.01%	302
2019 Q1	$4K	Hold	1,000	–	–	﹤0.01%	311
2018 Q4	$6K	Hold	1,000	–	–	0.01%	283
2018 Q3	$6K	Hold	1,000	–	–	﹤0.01%	278
2018 Q2	$4K	Hold	1,000	–	–	﹤0.01%	297
2018 Q1	$4K	Buy	+1,000	New	+$4.46K	﹤0.01%	338

Other funds holding PETX

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Founders Capital Management (Texas)'s PETX Position: Q3 2019 in Review

Founders Capital Management (Texas) sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2019, closing a stake of 1,000 shares — an estimated $5K sold.

Founders Capital Management (Texas) first reported a position in PETX in Q1 2018 and held it in 6 quarters. The position peaked at $6K in Q4 2018. 2 funds tracked by Wall St. Rank hold PETX as of Q3 2019.

Founders Capital Management (Texas) reported no remaining Aratana Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
Founders Capital Management (Texas) sold 1,000 Aratana Therapeutics, Inc. shares in Q3 2019, an estimated $5K.
Founders Capital Management (Texas) first reported a position in Aratana Therapeutics, Inc. in Q1 2018 and held it in 6 quarters.
Founders Capital Management (Texas)'s Aratana Therapeutics, Inc. position peaked at $6K in Q4 2018.
2 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2019.

Based on Founders Capital Management (Texas)'s 13F filing for Q3 2019, filed 10 Oct 2019.